卒中后早期神经影像与神经生理生物标志物用于活动能力预后预测的系统综述
该系统综述纳入23个独立研究样本(n=2678)的26篇报告,评估卒中后14天内测量的神经影像与神经生理生物标志物对14天后至24个月内活动能力结局的预后能力。多数分析为关联性分析(88%),判别/分类和验证分析很少,现有证据不足以支持这些早期生物标志物用于卒中后活动能力预后预测。
要点
- 早期皮质脊髓束结构和功能完整性指标常被研究,但多数关联较小或无统计学意义。
- 病灶位置和大小与活动能力结局的关联不一致,且研究方法异质性大。
- 现有证据不足以支持早期神经影像或神经生理生物标志物用于卒中后活动能力预后预测。
核心结论
- 当前证据不足以支持使用早期神经影像和神经生理生物标志物进行卒中后活动能力预后预测。
研究设计与样本
- 系统综述检索MEDLINE/EMBASE自建库至2026年5月,纳入卒中后14天内测量神经影像或神经生理生物标志物、并在14天后至24个月内评估活动能力结局的队列研究。
- 共纳入23个独立研究样本的26篇报告,合计n=2678名参与者,生物标志物测量中位时间为卒中后9.3天,结局评估时间在1至24个月之间。
主要发现
- 大多数分析为关联性分析(88%),判别/分类分析占10%,验证分析占2%。
- 皮质脊髓束结构和功能完整性指标常被研究,但多数发现效应较小或无统计学意义;病灶位置和大小 findings 也不一致。
- 常见方法学局限包括样本量小、偏倚风险中至高、效应量报告不足以及结局和随访时间点异质性大。
关键数值与推荐
- 预后研究偏倚风险采用Quality in Prognostic Studies工具评估。
- 生物标志物分析按统计分析方法分为关联、判别/分类和验证三类,相关统计量的大小作为预后能力的主要指标。
临床怎么用
- 目前不应将早期神经影像或神经生理生物标志物常规用于卒中后活动能力康复计划制定和目标设定。
- 临床决策仍需依赖其他已确立的临床评估信息,而非这些早期生物标志物。
局限性
- 纳入研究样本量小,偏倚风险中至高。
- 效应量报告不足,结局测量和随访时间点异质性大。
- 多数分析为关联性分析,判别/分类和验证分析很少。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
ObjectivePrognostication may help guide mobility rehabilitation planning and goal setting post-stroke. This systematic review aimed to examine the prognostic capacity of early neuroimaging and neurophysiological biomarkers of mobility outcomes up to 24 months post-stroke.Data sourcesMEDLINE/EMBASE was searched from inception to May 2026. Cohort studies that reported neuroimaging or neurophysiological biomarkers measured <14 days post-stroke and mobility outcome(s) assessed >14 days but ≤24 months post-stroke were included.Review methodsBiomarker analyses were classified by statistical analysis approach (association, discrimination/classification, validation). Magnitude of relevant statistical measures was the primary indicator of prognostic capacity. Risk of bias was assessed using the Quality in Prognostic Studies tool.ResultsTwenty-six reports from 23 independent study samples (n = 2678 participants) were included. Biomarkers were measured a median of 9.3 days post-stroke, and outcomes were assessed between 1 and 24 months. One hundred and nine biomarker analyses were identified (84 neuroimaging, 25 neurophysiological). Most analyses were association (88%), and few were discrimination/classification (10%) and validation (2%). Structural and functional corticospinal tract integrity metrics were frequently investigated, but findings were mostly small or non-significant. Lesion location and size findings were also commonly examined, but findings were inconsistent. Common methodological limitations included small sample sizes, moderate to high risk of bias, poor magnitude reporting and heterogeneous outcomes and follow-up timepoints.ConclusionCurrent evidence is insufficient to support the use of early neuroimaging and neurophysiological biomarkers for post-stroke mobility prognostication. International collaboration using harmonised methodologies, standardised statistical reporting and consistent outcome measures and timepoints is needed to generate meaningful prognostic information to guide rehabilitation.RegistrationCRD42022350771.
引用
- Levy C, Dalton EJ, Ferris JK, et al. A systematic review of early neuroimaging and neurophysiological biomarkers for post-stroke mobility prognostication. Clin Rehabil. 2026. PMID: 42606361. doi:10.1177/02692155261467649
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。